4932429P05Rik Inhibitors

The Ppp4r3c2 Inhibitors classification refers to a group of chemicals that may indirectly inhibit the protein phosphatase 4 regulatory subunit 3C2 by targeting protein phosphatase activity or signaling pathways in which PPP4R3C2 is involved. These compounds are not specific to PPP4R3C2 but can affect the cellular processes regulated by it. For instance, okadaic acid, calyculin A, cantharidin, endothall, fostriecin, tautomycin, and microcystin-LR are known to inhibit protein phosphatases such as PP1 and PP2A, which share similar functional domains and activities with PPP4R3C2. Therefore, by inhibiting these related phosphatases, these compounds can disrupt the signaling pathways that PPP4R3C2 might regulate.

Further, compounds like cyclosporin A and FK506 (tacrolimus) are known for their inhibition of calcineurin, another protein phosphatase. Their activity suggests possible indirect effects on the regulatory mechanisms where PPP4R3C2 is a component. Phenothiazines represent a class of compounds that inhibit PP2A and could similarly impact PPP4R3C2's function. Sphingosine and cerulenin are not direct inhibitors but can affect protein phosphatase activity by modulating lipid signaling pathways, which could intersect with PPP4R3C2's regulatory roles.